Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Feb;85(1):27-29.
doi: 10.18999/nagjms.85.1.27.

A never-ending FLT3 story

Hitoshi Kiyoi  1
Affiliations
Comment

A never-ending FLT3 story

Hitoshi Kiyoi. Nagoya J Med Sci. 2023 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

H Kiyoi received research funding from FUJIFILM, Kyowa-Kirin, Bristol-Myers Squibb, Otsuka, Perseus Proteomics, Daiichi Sankyo, Abbvie, CURED, Astellas Pharma, Chugai, Zenyaku Kogyo, Nippon Shinyaku, Eisai, Takeda, Sumitomo Dainippon Pharma, and Sanofi, and honoraria from Abbvie, Chugai, Astellas Pharma, and Novartis.

Comment on

References

    1. Kiyoi H. FLT3 inhibitors: recent advances and problems for clinical application. Nagoya J Med Sci. 2015;77(1–2):7–17. - PMC - PubMed
    1. Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454–464. doi: 10.1056/NEJMoa1614359. - DOI - PMC - PubMed
    1. Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728–1740. doi: 10.1056/NEJMoa1902688. - DOI - PubMed
    1. Cortes JE, Khaled S, Martinelli G, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):984–997. doi: 10.1016/S1470-2045(19)30150-0. - DOI - PubMed
    1. Kiyoi H, Kawashima N, Ishikawa Y. FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development. Cancer Sci. 2020;111(2):312–322. doi: 10.1111/cas.14274. - DOI - PMC - PubMed

LinkOut - more resources